TA1 vs VIP
A side-by-side research comparison of TA1 and VIP across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | TA1 | VIP |
|---|---|---|
| Full name | Thymosin Alpha-1 (TA1 - Clinical Form) | Vasoactive Intestinal Peptide |
| Category | Immune Support | Immune Support |
| Status | Approved internationally (not FDA-approved) | Research compound |
| Mechanism | Activates TLR2/9 on dendritic cells, promotes T-cell differentiation, and enhances cytokine-mediated immune signaling cascades. | Activates VPAC1 and VPAC2 receptors, raising intracellular cAMP. This dampens pro-inflammatory cytokine production, supports vasodilation and pulmonary function, and modulates regulatory T-cell activity. |
| Molecular weight | 3108.3 Da | ~3326 Da |
| Half-life | ~2-3 hours | Very short (~1-2 minutes in plasma) |
| Bioavailability | ~85% subcutaneous | Intranasal (most common in protocols); rapidly degraded systemically |
| Typical dose | 1.6 mg | ~50 mcg per spray |
| Frequency | 2x per week | 1-4x daily |
| Route | Subcutaneous injection | Intranasal spray |
TA1 reported benefits
- Standardized immune enhancement
- Proven antiviral adjunct
- Cancer immunotherapy support
- Vaccine response enhancement
VIP reported benefits
- Broad anti-inflammatory effect
- Supports pulmonary and vascular function
- Immune modulation (regulatory T cells)
- Used in chronic inflammatory response protocols
Related comparisons
Research and educational reference only. Not medical advice.